Incyte Corporation has published a document highlighting data on myeloproliferative neoplasms (MPNs) from the EHA 2025 event. The document includes insights into essential thrombocythemia, research on mutant calreticulin in MPNs, and phase 1 data on a novel monoclonal antibody targeting mutant calreticulin. The full document can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.